CTBO / Cantabio Pharmaceuticals, Inc. - SEC-arkiveringar, Årsredovisning, Fullmaktsutlåtande

CTBO / Cantabio Pharmaceuticals Inc. 15-12G - - FORM 15

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 000-54905 Cantabio Pharmaceuticals Inc. (Exact name of registrant as specifi

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 21, 2019 Date of Report Cantabio Pharmaceuticals Inc. (Exact name of small business issuer as specified in its charter) Delaware 000-54905 99-0373067 (State or other jurisdiction of incorporation) (Commission File Number) (IRS E

STATE OF DELAWARE CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION

Exhibit 3.1 STATE OF DELAWARE CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION The corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware does hereby certify: FIRST: That at a meeting of the Board of Directors of Cantabio Pharmaceuticals Inc. resolutions were duly adopted setting forth a proposed amendment of the Certificate of Incorp

CTBO / Cantabio Pharmaceuticals Inc. / Cantabio Pharmaceuticals Inc. - AMENDMENT #4

SC 13E3/A 1 ctbos13e3a.htm AMENDMENT #4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 4 to SCHEDULE 13E3 RULE 13E3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 CANTABIO PHARMACEUTICALS INC. (Name of the Issuer) Cantabio Pharmaceuticals Inc. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title

CTBO / Cantabio Pharmaceuticals Inc. 10-Q - Quarterly Report - QUARTERLY REPORT

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2018 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54905 Cantabio Pharmaceuticals Inc. (Exact

CTBO / Cantabio Pharmaceuticals Inc. DEF 14C - - DEFINITIVE INFORMATION STATEMENT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C (Rule 14c-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [ ] Preliminary Information Statement [ ] Confidential, For Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [X] Definitive Information Statement CANTABIO PHARMACEUTICALS IN

CTBO / Cantabio Pharmaceuticals Inc. / Cantabio Pharmaceuticals Inc. - AMENDMENT #3

SC 13E3/A 1 ctbos13e3a.htm AMENDMENT #3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 3 to SCHEDULE 13E3 RULE 13E3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 CANTABIO PHARMACEUTICALS INC. (Name of the Issuer) Cantabio Pharmaceuticals Inc. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title

CTBO / Cantabio Pharmaceuticals Inc. PRER14C AMENDMENT NO. 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Amendment No. 2 (Rule 14c-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [X] Preliminary Information Statement [ ] Confidential, For Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [ ] Definitive Information Statement CANTABIO PH

CTBO / Cantabio Pharmaceuticals Inc. / Cantabio Pharmaceuticals Inc. - AMENDMENT NO. 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 2 to SCHEDULE 13E3 RULE 13E3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 CANTABIO PHARMACEUTICALS INC. (Name of the Issuer) Cantabio Pharmaceuticals Inc. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 13808X104 (CUSIP

CTBO / Cantabio Pharmaceuticals Inc. CORRESP - -

CANTABIO PHARMACEUTICALS INC. 2225 East Bayshore Road Palo Alto, California 94303 Tel. 8442002826 May 15, 2019 VIA EDGAR Perry J. Hindin Special Counsel Office of Mergers & Acquisitions U.S. Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549-4720 Mail Stop 4546 Re: Cantabio Pharmaceuticals Inc. Preliminary Information Statement on Schedule 14C Filed on March 22, 2019 File N

CTBO / Cantabio Pharmaceuticals Inc. PRER14C AMENDMENT NO. 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Amendment No. 1 (Rule 14c-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [X] Preliminary Information Statement [ ] Confidential, For Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [ ] Definitive Information Statement CANTABIO PH

CTBO / Cantabio Pharmaceuticals Inc. CORRESP - -

CANTABIO PHARMACEUTICALS INC. 2225 East Bayshore Road Palo Alto, California 94303 Tel. 8442002826 May 8, 2019 VIA EDGAR Perry J. Hindin Special Counsel Office of Mergers & Acquisitions U.S. Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549-4720 Mail Stop 4546 Re: Cantabio Pharmaceuticals Inc. Preliminary Information Statement on Schedule 14C Filed on March 22, 2019 File No

CTBO / Cantabio Pharmaceuticals Inc. / Cantabio Pharmaceuticals Inc. - AMENDMENT NO. 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to SCHEDULE 13E3 RULE 13E3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 CANTABIO PHARMACEUTICALS INC. (Name of the Issuer) Cantabio Pharmaceuticals Inc. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 13808X104 (CUSIP

CTBO / Cantabio Pharmaceuticals Inc. CORRESP - -

Cantabio Pharmaceuticals Inc. April 10, 2019 Christine Westbrook Suzanne Hayes U.S. Securities and Exchange Commission Washington, D.C. 20549 Via EDGAR Re: Cantabio Pharmaceuticals Inc. Preliminary Information Statement on Schedule 14C Filed March 22, 2019 File No. 000-54906 Dear Ms. Westbrook and Ms. Hayes: This letter is in response to your letter of March 27, 2019 in which you provided a commen

CTBO / Cantabio Pharmaceuticals Inc. / Cantabio Pharmaceuticals Inc. - TRANSACTION STATEMENT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13E3 RULE 13E3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 CANTABIO PHARMACEUTICALS INC. (Name of the Issuer) Cantabio Pharmaceuticals Inc. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 13808X104 (CUSIP Number of Class of

CTBO / Cantabio Pharmaceuticals Inc. PRELIMINARY INFORMATION STATEMENT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [X] Preliminary Information Statement [ ] Confidential, For Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [ ] Definitive Information Statement CANTABIO PHARMACEUTICALS INC. (Name of Reg

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 13, 2019 Date of Report Cantabio Pharmaceuticals Inc. (Exact name of small business issuer as specified in its charter) Delaware 000-54905 99-0373067 (State or other jurisdiction of incorporation) (Commission File Number) (IRS

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 23, 2018 Date of Report Cantabio Pharmaceuticals Inc. (Exact name of small business issuer as specified in its charter) Delaware 000-54905 99-0373067 (State or other jurisdiction of incorporation) (Commission File Number) (I

CTBO / Cantabio Pharmaceuticals Inc. QUARTERLY REPORT (Quarterly Report)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54905 Cantabio Pharmaceuticals Inc. (Exac

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 7, 2018 Date of Report Cantabio Pharmaceuticals Inc. (Exact name of small business issuer as specified in its charter) Delaware 000-54905 99-0373067 (State or other jurisdiction of incorporation) (Commission File Number) (I

CTBO / Cantabio Pharmaceuticals Inc. PRIMARY DOCUMENT (Quarterly Report)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54905 Cantabio Pharmaceuticals Inc. (Exact name of

CTBO / Cantabio Pharmaceuticals Inc. PRIMARY DOCUMENT

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12B-25 NOTIFICATION OF LATE FILING SEC File Number 000-54906 Form 10-Q For Period Ending: June 30, 2018 PART I: REGISTRANT INFORMATION Full Name of Registrant: Cantabio Pharmaceuticals Inc. Address of Principal Executive Office: 2225 East Bayshore Road #223 Palo Alto, California (650) 320-1765 PART II: RULES 12B-25(B) AND (C) It is

CTBO / Cantabio Pharmaceuticals Inc. PRIMARY DOCUMENT (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K X ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-54906 CANTABIO PHARMACEUTICALS INC.

CTBO / Cantabio Pharmaceuticals Inc. PRIMARY DOCUMENT

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12B-25 NOTIFICATION OF LATE FILING SEC File Number 000-53232 Form 10-K For Period Ending: March 31, 2018 PART I: REGISTRANT INFORMATION Full Name of Registrant: Cantabio Pharmaceuticals Inc. Address of Principal Executive Office: 1250 Oakmead Pkwy Sunnyvale, CA 94085-4037 (408) 501-8893 PART II: RULES 12B-25(B) AND (C) It is anticip

Amendment Agreement, dated June 5, 2018

EX-10.2 3 exhibit102amendmentagreem.htm MATERIAL CONTRACTS AMENDMENT AGREEMENT This Amendment Agreement (the “Agreement”), dated as of June 5, 2018, is entered into by and between Cantabio Pharmaceuticals Inc., a Delaware corporation (the “Company”), and YA II PN, Ltd. (the “Note Holder”) and is the basis for the amendment of four convertible notes (as discussed below) the Company issued to the No

Securities Purchase Agreement, dated June 5, 2018

SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of June 5, 2018, is between CANTABIO PHARMACEUTICALS INC.

Form of Debenture

NEITHER THIS DEBENTURE NOR THE SECURITIES INTO WHICH THIS DEBENTURE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE.

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

8-K 1 cantabio8k.htm PRIMARY DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 5, 2018 Date of Report Cantabio Pharmaceuticals Inc. (Exact name of small business issuer as specified in its charter) Delaware 000-54905 99-0373067 (State or other jurisdiction of incorpora

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

8-K 1 a8-kapril2018.htm PRIMARY DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 12, 2018 Date of Report Cantabio Pharmaceuticals Inc. (Exact name of small business issuer as specified in its charter) Delaware 000-54905 99-0373067 (State or other jurisdiction of in

FORM OF DEBT CONVERSION AGREEMENT

FORM OF DEBT CONVERSION AGREEMENT This Debt Conversion Agreement (the “Agreement”) is entered into as of [March , 2018] by and between [-] (“Investor”) and Cantabio Pharmaceuticals Inc.

CTBO / Cantabio Pharmaceuticals Inc. PRIMARY DOCUMENT (Quarterly Report)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54905 Cantabio Pharmaceuticals Inc. (Exact nam

CTBO / Cantabio Pharmaceuticals Inc. PRIMARY DOCUMENT

Blueprint U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12B-25 NOTIFICATION OF LATE FILING SEC File Number 000-54906 Form 10-Q For Period Ending: December 31, 2017 PART I: REGISTRANT INFORMATION Full Name of Registrant: Cantabio Pharmaceuticals Inc. Address of Principal Executive Office: 2225 East Bayshore Road #223 Palo Alto, California (650)320-1765 PART II: RULES 12B-25(B) A

CANTABIO PHARMACEUTICALS INC. Secured Convertible Debenture

EX-10.4 5 cantabio-yadebenturenov20.htm MATERIAL CONTRACTS NEITHER THIS DEBENTURE NOR THE SECURITIES INTO WHICH THIS DEBENTURE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), A

AMENDMENT AGREEMENT

EX-10.3 4 cantabio-yaamendmentagree.htm MATERIAL CONTRACTS AMENDMENT AGREEMENT This Amendment Agreement (the “Agreement”), dated as of November 20, 2017, is entered into by and between Cantabio Pharmaceuticals Inc., a Delaware corporation (the “Company”), and YA II PN, Ltd. (the “Note Holder”) and is the basis for the amendment of three convertible notes (as discussed below) the Company issued to

Security Agreement, dated November 20, 2017

Blueprint SECURITY AGREEMENT (in favor of YA II PN, Ltd.) THIS SECURITY AGREEMENT (the ?Agreement?) is entered into as of November 20, 2017 by and among (i) Cantabio Pharmaceuticals Inc., a Delaware corporation (the ?Issuer?), and (ii) any subsidiary and affiliate of the Issuer listed on Schedule 1 attached hereto either now or joined in the future (the ?Subsidiaries?; and jointly, severally, and

SECURITIES PURCHASE AGREEMENT

Blueprint SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this ?Agreement?), dated as of November 20, 2017, is between CANTABIO PHARMACEUTICALS INC.

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

8-K 1 cantabionovember20178-k.htm PRIMARY DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 20, 2017 Date of Report Cantabio Pharmaceuticals Inc. (Exact name of small business issuer as specified in its charter) Delaware 000-54905 99-0373067 (State or other jurisdi

CTBO / Cantabio Pharmaceuticals Inc. PRIMARY DOCUMENT (Quarterly Report)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54906 Cantabio Pharmaceuticals Inc. (Exact na

CTBO / Cantabio Pharmaceuticals Inc. QUARTERLY REPORT ON FORM 10-Q (Quarterly Report)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q X QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54905 Cantabio Pharmaceuticals Inc. (Exact name of

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 32.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The undersigned, Simon Peace, the Chief Financial Officer of Cantabio Pharmaceuticals Inc. (the “Company”) hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that,

Cantabio Pharmaceuticals ESP

Cantabio Pharmaceuticals Inc. 1250 Oakmead Pkwy Sunnyvale, California Telephone: 844-200-2826 August 10, 2017 VIA EDGAR Suzanne Hayes Jeffery Gabor Joseph McCann Ibolya Ignat Mary Mast U.S. Securities and Exchange Commission Re: Cantabio Pharmaceuticals Inc. (the ?Registrant?) Registration Statement on Form S-1 (as amended, the ?Registration Statement?) File No. 333-217749 Request for Acceleration

Cantabio Pharmaceuticals ESP

Cantabio Pharmaceuticals Inc. August 3, 2017 Suzanne Hayes Joseph McCann Jeffery Gabor U.S. Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549-4720 Mail Stop 4546 Via EDGAR Re: Amendment No. 1 to Registration Statement on Form S-1 Filed July 14, 2017 File No. 333-217749 Form 10-K for Fiscal Year Ended March 31, 2017 File No. 000-54906 Dear Ms. Hayes, Mr. McCann and Mr. Gabo

Cantabio Pharmaceuticals AMENDMENT NO. 1 TO REGISTRATION STATEMENT ON FORM S-1

As filed with the Securities and Exchange Commission on July 14, 2017 Registration No.

Cantabio Pharmaceuticals NOTIFICATION OF LATE FILING FOR FORM 10-K ANNUAL REPORT

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12B-25 NOTIFICATION OF LATE FILING SEC File Number 000-53232 Form 10-K For Period Ending: March 31, 2017 PART I: REGISTRANT INFORMATION Full Name of Registrant: Cantabio Pharmaceuticals Inc. Address of Principal Executive Office: 1250 Oakmead Pkwy Sunnyvale, CA 94085-4037 (408) 501-8893 PART II: RULES 12B-25(B) AND (C) It is anticip

CTBO / Cantabio Pharmaceuticals Inc. ANNUAL REPORT ON FORM 10-K (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K X ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2017 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-54906 CANTABIO PHARMACEUTICALS INC.

Cantabio Pharmaceuticals ESP

Cantabio Pharmaceuticals Inc. June 13, 2017 Suzanne Hayes Joseph McCann Jeffery Gabor U.S. Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549-4720 Mail Stop 4546 Via EDGAR Re: Cantabio Pharmaceuticals Inc. Registration Statement on Form S-1 Filed March 1, 2017 File No. 333-217749 Dear Ms. Hayes, Mr. McCann and Mr. Gabor: This letter is in response to your letter of June 1,

CAMBRIDGE ENTERPRISE LIMITED (“CE”) (1) CANTABIO PHARMACEUTICALS INC. (2)

DATED CAMBRIDGE ENTERPRISE LIMITED (?CE?) (1) and CANTABIO PHARMACEUTICALS INC. (2) (?Licensee?) DATA AND KNOW-HOW LICENCE AGREEMENT Case No: Tot-3254-16 Contents 1 Definitions and Interpretations 3 6.3 Infringement of the Data-Based 1.1 Definitions 3 Patents 17 1.2 Interpretation 6 6.4 Infringement of third party rights 17 1.3 Schedules 7 7 Warranties and liability 17 2 Grant of rights 7 7.1 Stat

Cantabio Pharmaceuticals ESP

Cantabio Pharmaceuticals Inc. May 5, 2017 Suzanne Hayes Joseph McCann Jeffery Gabor U.S. Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549-4720 Mail Stop 4546 Via EDGAR Re: Cantabio Pharmaceuticals Inc. Registration Statement on Form S-1 Filed March 1, 2017 File No. 333-216370 Dear Ms. Hayes, Mr. McCann and Mr. Gabor: This letter is in response to your letter of March 29,

As filed with the Securities and Exchange Commission on May 5, 2017

S-1 1 cantabios1.htm REGISTRATION STATEMENT ON FORM S-1 As filed with the Securities and Exchange Commission on May 5, 2017 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CANTABIO PHARMACEUTICALS INC. (Name of Issuer in Its Charter) Delaware (State or other jurisdiction of incorporation)

AMENDED AND RESTATED SECURITIES PURCHASE AGREEMENT

AMENDED AND RESTATED SECURITIES PURCHASE AGREEMENT THIS AMENDED AND RESTATED SECURITIES PURCHASE AGREEMENT (the ?Amended Agreement?), dated as of May 3, 2017, amends and restates that Securities Purchase Agreement, dated January 25, 2017 (the ?Original SPA?), between CANTABIO PHARMACEUTICALS INC.

CANTABIO PHARMACEUTICALS INC. Secured Convertible Debenture

NEITHER THIS DEBENTURE NOR THE SECURITIES INTO WHICH THIS DEBENTURE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE.

Cantabio Pharmaceuticals REGISTRATION WITHDRAWAL REQUEST ON FORM RW

May 4, 2017 VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission Re: Cantabio Pharmaceuticals Inc. Registration Statement on Form S-1 (File No. 333-216370) Application for Withdrawal Ladies and Gentlemen: Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended (the ?Act?), Cantabio Pharmaceuticals Inc., a corporation organized under the laws of th

Cantabio Pharmaceuticals REGISTRATION STATEMENT ON FORM S-1

S-1 1 cantas1.htm REGISTRATION STATEMENT ON FORM S-1 As filed with the Securities and Exchange Commission on March 1, 2017 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CANTABIO PHARMACEUTICALS INC. (Name of Issuer in Its Charter) Delaware (State or other jurisdiction of incorporation)

LOAN AGREEMENT (“The Agreement”) As of the 8th of December 2016

LOAN AGREEMENT (?The Agreement?) As of the 8 th of December 2016 BETWEEN: Dr. Max Zhu, residing at Flat E, 6/F, Tower 2, Lake Silver, Ma On Shan, Hong Kong, (?the Lender?) and Cantabio Pharmaceuticals, Inc., 2150 Oakmead Parkway, Sunnyvale, CA 94085 (?the Borrower?) WHEREAS: The borrower has requested a loan from the Lender for working capital purposes and the Lender has agreed to grant such loan

Cantabio Pharmaceuticals QUARTERLY REPORT ON FORM 10-Q (Quarterly Report)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q X QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2016  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54905 Cantabio Pharmaceuticals Inc. (Exact nam

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

8-K 1 canta8k.htm REPORT ON FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 25, 2017 Date of Report Cantabio Pharmaceuticals Inc. (Exact name of small business issuer as specified in its charter) Delaware 000-54905 99-0373067 (State or other jurisdiction of incorp

Cantabio Pharmaceuticals announces Definitive Funding Agreement of up to $600,000 from Yorkville Advisors Global

EX-99.1 6 pressrelease.htm PRESS RELEASE Cantabio Pharmaceuticals announces Definitive Funding Agreement of up to $600,000 from Yorkville Advisors Global SAN FRANCISCO, Calif., February 1, 2017 — Cantabio Pharmaceuticals, Inc. (OTCQB: CTBO), a biopharmaceutical company developing novel disease modifying therapies for Alzheimer’s, Parkinson’s and other related neurodegenerative diseases is pleased

FORM OF DEBENTURE

EX-10.4 5 debentureform.htm FORM OF DEBENTURE FORM OF DEBENTURE NEITHER THIS DEBENTURE NOR THE SECURITIES INTO WHICH THIS DEBENTURE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT

REGISTRATION RIGHTS AGREEMENT

REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ? Agreement?), dated as of January 25, 2017, by and among CANTABIO PHARMACEUTICALS INC.

SECURITIES PURCHASE AGREEMENT

EX-10.1 2 spa.htm SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of January 25, 2017, is between CANTABIO PHARMACEUTICALS INC., a company incorporated under the laws of the State of Delaware, with headquarters located at 1250 Oakmead Pkwy, Sunnyvale, California, 94085 (the “Company”), and each of the investors listed on t

SECURITY AGREEMENT (in favor of YA II PN, Ltd.)

SECURITY AGREEMENT (in favor of YA II PN, Ltd.) THIS SECURITY AGREEMENT (the ? Agreement?) is entered into as of January 25, 2017 by and among (i) Cantabio Pharmaceuticals Inc., a Delaware corporation (the ? Issuer?), and (ii) any subsidiary and affiliate of the Issuer listed on Schedule 1 attached hereto either now or joined in the future (the ? Subsidiaries?; and jointly, severally, and collecti

Cantabio Pharmaceuticals COMPANY FORM 10-Q FOR PERIOD ENDING 9-30-2016.. (Quarterly Report)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q X QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54905 Cantabio Pharmaceuticals Inc. (Exact na

Cantabio Pharmaceuticals (Quarterly Report)

form10q.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q X QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54905 Cantabio Pharmaceuticals Inc. (E

Exhibit 10.2, 1

EX-10.2 3 exhibit10-2.htm Exhibit 10.2 LOAN AGREEMENT Date: December 10th, 2015 For value received, the undersigned Gardedam Therapeutics, Inc. (the "Borrower"), at 1027 Bryant St Unit A, Palo Alto, CA 94301 promises to pay to the order of Eden Professional Ltd. (the "Lender"), at The Old Bell Barn, Ardeley, Hertfordshire SG2 7AH, UK (or at such other place as the Lender may designate in writing),

LOAN AGREEMENT (“The Agreement”)

exhibit10-6.htm Exhibit 10.6 LOAN AGREEMENT (?The Agreement?) As of the of 2015 BETWEEN: Gardedam Therapeutics Inc. whose registered address is 2443 Fillmore St #380-? 8102, San Francisco, CA 94115, USA (?the Lender?) and Capro Ltd. whose registered address is 39 Dresden Road, London, N19 3BE, UK (?the Borrower?) WHEREAS: The borrower has requested a loan from the Lender for working capital purpos

CONFIDENTIAL PRIVATE PLACEMENT SUBSCRIPTION AGREEMENT (Accredited Investors)

exhibit10-5.htm Exhibit 10.5 THE SECURITIES TO WHICH THIS SUBSCRIPTION AGREEMENT RELATES ARE SPECULATIVE AND INVOLVE A HIGH DEGREE OF RISK. THEY SHOULD BE PURCHASED ONLY BY PERSONS WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. THE SECURITIES TO WHICH THIS SUBSCRIPTION AGREEMENT RELATES ARE BEING OFFERED AND SOLD IN RELIANCE UPON EXEMPTIONS FROM REGISTRATION UNDER APPLICABLE FEDERAL AND STATE SEC

TRADE SECRET LICENSE AGREEMENT

exhibit10-3.htm TRADE SECRET LICENSE AGREEMENT THIS TRADE SECRET LICENSE AGREEMENT is made and entered into as of April 1, 2016 (?Effective Date?), by and between PURDUE RESEARCH FOUNDATION, a statutory body corporate formed and existing under the Indiana Foundation or Holding Companies Act of 1921 (?PRF?), and CANTABIO PHARMACEUTICALS INC., a Deleware corporation, (?LICENSEE?) collectively referr

Cantabio Pharmaceuticals (Annual Report)

form10-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K X ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2016 or ?TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-54905 CANTABIO PHARMACEU

LOAN AGREEMENT

exhibit10-1.htm Exhibit 10.1 LOAN AGREEMENT $2500.00 Date: June 23, 2015 For value received, the undersigned Gardedam Therapeutics, Inc. (the "Borrower"), at 1027 Bryant St Unit A, Palo Alto, CA 94301 promises to pay to the order of Gergely Toth (the "Lender"), at Disz ter 10, Budapest Hngary, an amount of USD $17,193 (US Dollars) as requested by the Borrower, with no interest. I. TERMS OF REPAYME

Agreement

exhibit10-4.htm Exhibit 10.4 Agreement Between the following parties: Regarding the work carried out and the results of that work (?the Results?) NovAliX Deutschland GmbH (?NOVALIX?), a German corporation located at Seckenheimer Landstrasse 4, D-68163 Mannheim, Germany, represented by its Gesch?ftsf?hrer, Mr Stephan JENN. The (?COMPANY?), CANTABIO PHARAMCEUTICALS, Inc. (?CANTABIO?), headquartered

Cantabio Pharmaceuticals 0-K

formnt10-k.htm U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12B-25 NOTIFICATION OF LATE FILING SEC File Number 000-53232 Form 10-K For Period Ending: March 31, 2016 PART I: REGISTRANT INFORMATION Full Name of Registrant: Cantabio Pharmaceuticals Inc. Address of Principal Executive Office: 1250 Oakmead Pkwy Sunnyvale, CA 94085-4037 (408) 501-8893 PART II: RULES 12B-25(B) AND (C

Cantabio Pharmaceuticals /A (Quarterly Report)

form10-qa.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) X QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2015 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00

Current Report

8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 21, 2016 Date of Report Cantabio Pharmaceuticals Inc. (Exact name of small business issuer as specified in its charter) Delaware 000-54905 99-0373067 (State or other jurisdiction of incorporation) (Commission

Cantabio Pharmaceuticals (Quarterly Report)

form10-q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q X QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Deccember 31, 2015 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54905 Cantabio Pha

Current Report

8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 18, 2016 Date of Report Cantabio Pharmaceuticals Inc. (Exact name of small business issuer as specified in its charter) Delaware 000-54905 99-0373067 (State or other jurisdiction of incorporation) (Commissi

February 23, 2016

EX-16.1 2 exhibit16-1.htm EXHIBIT 16.1 February 23, 2016 Securities and Exchange Commission 450 Fifth Street N.W. Washington, DC 20549 We have read the statements of Cantabio Pharmaceuticals, Inc., pertaining to our firm included under Item 4.01 of Form 8-K dated February 23, 2016 and agree with such statements as they pertain to our firm. Sincerely, /s/ KLJ & Associates, LLP

Cantabio Pharmaceuticals 0-Q

formnt10-q.htm U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12B-25 NOTIFICATION OF LATE FILING SEC File Number 000-53232 Form 10-Q For Period Ending: December 31, 2015 PART I: REGISTRANT INFORMATION Full Name of Registrant: Cantabio Pharmaceuticals Inc. Address of Principal Executive Office: 2225 East Bayshore Road #223 Palo Alto, California (650)320-1765 PART II: RULES 12B-25

LOAN AGREEMENT (“The Agreement”) As of the 21st of July 2015

EXHIBIT 10-7 LOAN AGREEMENT (?The Agreement?) As of the 21st of July 2015 BETWEEN: Gardedam Therapeutics Inc.

Gardedam Therapeutics Inc. (Simple Agreement for Future Equity) July 21st 2015

EXHIBIT 10-11 THIS INSTRUMENT AND ANY SECURITIES ISSUABLE PURSUANT HERETO HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES.

LOAN AGREEMENT (“The Agreement”) As of the 8th of September 2015

EXHIBIT 10-9 LOAN AGREEMENT (?The Agreement?) As of the 8th of September 2015 BETWEEN: Gardedam Therapeutics Inc.

LOAN AGREEMENT (“The Agreement”) As of the 22nd of July 2015

EXHIBIT 10-8 LOAN AGREEMENT (?The Agreement?) As of the 22nd of July 2015 BETWEEN: Gardedam Therapeutics Inc.

LOAN AGREEMENT (“The Agreement”) As of the 26th of June 2015

EXHIBIT 10-6 LOAN AGREEMENT (?The Agreement?) As of the 26th of June 2015 BETWEEN: Gardedam Therapeutics Inc.

Agreement

EXHIBIT 10-12 Agreement Between the following parties: Regarding the work carried out and the results of that work (?the Results?) NovAliX Deutschland GmbH (?NOVALIX?), a German corporation located at Seckenheimer Landstrasse 4, D-68163 Mannheim, Germany, represented by its Gesch?ftsf?hrer, Mr Stephan JENN.

Investment Agreement

EX-10.10 11 exhibit10-10.htm EXHIBIT 10-10 Investment Agreement Entered into on [date] between [entity/entities x] (the “Investors”), of [address] and Cantabio Pharmaceuticals, Inc. (the “Corporation”), a Delaware corporation, of 2225 East Bayshore Road #223, Palo Alto, CA, USA. Recitals The Investors are to provide an investment of a total of USD $1,500,000 (the “Investment”) in the Corporation t

LOAN AGREEMENT

EXHIBIT 10-5 LOAN AGREEMENT $2500.00 Date: June 23, 2015 For value received, the undersigned Lion Consulting Group Inc. (the "Borrower"), promises to pay to the order of Capro Ltd (the "Lender"), the sum of $2500.00 with no interest. I. TERMS OF REPAYMENT A. Payments The unpaid principal and accrued interest shall be payable in full on any future date on which the Lender demands repayment (the "Du

CONSULTING AGREEMENT

EX-10.3 4 exhibit10-3.htm EXHIBIT 10-3 CONSULTING AGREEMENT 1. This Consulting Agreement, dated as of 1st April, 2015, is entered into between EDEN PROFESSIONAL LTD of THE OLD BELL BARN, ARDELEY, HERTS, UK (the “Service Provider”) and GARDEDAM THERAPEUTICS, INC. of 2443 Fillmore St #380-8102, San Francisco, CA 94115 (the “Company”). Whereas, the Company desires to engage the Service Provider to pr

AGREEMENT AND PLAN OF MERGER

EXHIBIT 10-1 AGREEMENT AND PLAN OF MERGER This Agreement and Plan of Merger (the "Agreement") is made as of this 17th day of December 2015 by and among (i) Cantabio Pharmaceuticals Inc.

Change in Shell Company Status, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 17, 2015 Date of Report Cantabio Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 000-54905 99-0373067 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer

CONSULTING AGREEMENT

EXHIBIT 10-4 CONSULTING AGREEMENT 1. This Consulting Agreement, dated as of 1st April, 2015, is entered into between CAPRO LTD. of 39 DRESDEN ROAD, LONDON, UK (the ?Service Provider?) and GARDEDAM THERAPEUTICS, INC. of 2443 Fillmore St #380-8102, San Francisco, CA 94115 (the ?Company?). Whereas, the Company desires to engage the Service Provider to provide the Services of a part-time Chief Operati

CONSULTING AGREEMENT

CONSULTING AGREEMENT 1. This Consulting Agreement, dated as of 1st April, 2015, is entered into between TOTH AND ASSOCIATES LTD. of 154 WEST GREEN ROAD, LONDON N15 5AS, UK (the ?Service Provider?) and GARDEDAM THERAPEUTICS, INC. of 2443 Fillmore St #380-8102, San Francisco, CA 94115 (the ?Company?). Whereas, the Company desires to engage the Service Provider to provide the Services of a part-time

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 X QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54905 Cantabio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q X QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54905 Cantabio Pharmaceuticals

Cantabio Pharmaceuticals 0-Q

form10-q.htm U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12B-25 NOTIFICATION OF LATE FILING SEC File Number 000-53232 Form 10-Q For Period Ending: September 30, 2015 PART I: REGISTRANT INFORMATION Full Name of Registrant: Cantabio Pharmaceuticals Inc. Address of Principal Executive Office: 2225 East Bayshore Road #223 Palo Alto, California (650)320-1765 PART II: RULES 12B-25(

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 29, 2015 Date of Report Cantabio Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 000-54905 99-0373067 (State or other jurisdiction of incorporation) (Commission File Number)

STATE OF DELAWARE CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION

exhibit3-1.htm EXHIBIT 3.1 STATE OF DELAWARE CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION The corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware does hereby certify: FIRST: That at a meeting of the Board of Directors of Lion Consulting Group, Inc. resolutions were duly adopted setting forth a proposed amendment of the Certific

Cantabio Pharmaceuticals 14C

formdef14c.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: o Preliminary Information Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) X Definitive Information Statement Lion Consulting Group, Inc. (Name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q X QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54905 Lion Consulting Group, Inc. (E

Cantabio Pharmaceuticals 0-Q

formnt10-q.htm U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12B-25 NOTIFICATION OF LATE FILING SEC File Number 000-54905 Form 10-Q For Period Ending: June 30, 2015 PART I: REGISTRANT INFORMATION Full Name of Registrant: Lion Consulting Group, Inc. Address of Principal Executive Office: Albulastrasse 55 Zurich Switzerland V8 8048 +41 44 512 51 00 PART II: RULES 12B-25(B) AND (C

Cantabio Pharmaceuticals 14C

pre14c.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: X Preliminary Information Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) o Definitive Information Statement Lion Consulting Group, Inc. (Name of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: March 31, 2015 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54905 Lion Consulting Group, Inc. (Exa

Cantabio Pharmaceuticals 14C

form14c.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: X Preliminary Information Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) o Definitive Information Statement Lion Consulting Group, Inc. (Name of

Cantabio Pharmaceuticals 14C

form14c.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: X Preliminary Information Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) o Definitive Information Statement Lion Consulting Group, Inc. (Name of

Cantabio Pharmaceuticals 4F1

sch14f1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14F-1 INFORMATION STATEMENT PURSUANT TO SECTION 14(F) OF THE SECURITIES EXCHANGE ACT OF 1934 LION CONSULTING GROUP INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-54906 (Commission File No.) 99-0373067 (IRS Employer Identification No.)

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 22, 2015 Date of Report Lion Consulting Group, Inc. (Exact name of registrant as specified in its charter) Delaware 000-54905 99-0373067 (State or other jurisdiction of incorporation) (Commission File Number) (I

Cantabio Pharmaceuticals 0-K

formnt10-k.htm U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number: 000-54906 Notification of Late Filing (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form N-SAR For Period Ended: March 31, 2015 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2014 [ ] Transition Report pursu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2014 [ ] Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54906 Lion Consulting Group, I

CTBO / Cantabio Pharmaceuticals Inc. NT 10-Q - - MAINBODY

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number: 000-54906 Notification of Late Filing (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form N-SAR For Period Ended: December 31, 2014 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2014 [ ] Transition Report purs

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2014 [ ] Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54906 Lion Consulting Group,

CTBO / Cantabio Pharmaceuticals Inc. NT 10-Q - - MAINBODY

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number: 000-54906 Notification of Late Filing (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form N-SAR For Period Ended: September 30, 2014 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2014 [ ] Transition Report pursuant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2014 [ ] Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54906 Lion Consulting Group, Inc.

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 4, 2014 Lion Consulting Group Inc. (Exact name of registrant as specified in its charter) Delaware 000-54906 99-0373067 (State or other jurisdiction of incorporation) (Commission File Number

Letter from Silberstein Ungar, PLLC to the Securities and Exchange Commission

Silberstein Ungar, PLLC CPAs and Business Advisors Phone (248) 203-0080 Fax (248) 281-0940 30600 Telegraph Road, Suite 2175 Bingham Farms, MI 48025-4586 www.

CTBO / Cantabio Pharmaceuticals Inc. NT 10-Q - - MAINBODY

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number: 000-54906 Notification of Late Filing (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR For Period Ended: June 30, 2014 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Tra

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 22, 2014 Lion Consulting Group Inc. (Exact name of registrant as specified in its charter) Delaware 000-54906 99-0373067 (State or other jurisdiction of incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2014 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the transition period from to Commission file number: 000-54906 LION CONSULTING GROUP INC. (Exact n

CTBO / Cantabio Pharmaceuticals Inc. NT 10-K - - MAINBODY

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number: 000-54906 Notification of Late Filing (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form N-SAR For Period Ended: March 31, 2014 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Tr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2013 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-54906 LION CONSU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2013 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-54906 LION CONS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2013 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-54906 LION CONSULTIN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2013 Commission File No. 000-54906 LION CONSULT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2013 Commission File No. 000-54906 LION CONSULTING GROUP INC. (Exact name of registrant as specified in its charter) Delaware 99-0373067 (State or other jurisdiction of (I.R.S. Employer incorporati

CTBO / Cantabio Pharmaceuticals Inc. / Wagner Philippe - SC 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Lion Consulting Group Inc. (Name of Issuer) Common Stock, $.001 Par Value (Title of Class of Securities) 15619Q104 (CUSIP Number) Philippe Wagner c/o Lion Consulting Group Inc. Seestrasse 129 8704 Herriberg Switzerland Tel: (760) 299-3516 (Name, Address and Telephone Numbe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2012 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-54906 LION CONSU